This is a randomized, open-label study to evaluate the safety/tolerability and PK/PD drug-drug interactions between DWP14012 and aspirin when administered in combination.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
24
Seoul National University Hospital
Seoul, South Korea
Cmax of aspirin
Time frame: Up to 21 days
Cmax,ss of DWP14012
Time frame: Up to 13 days
Emax
Time frame: Up to 21 days
AUClast of aspirin
Time frame: Up to 21 days
AUCτ,ss of DWP14012
Time frame: Up to 13 days
time to Emax
Time frame: Up to 21 days
AUEC
Time frame: Up to 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.